



MINUTES: MARCH 14, 2021

TYPE OF MEETING	Perinatal Business Meeting
FACILITATOR	Eumenia Castro, MD, PhD, Chair, Perinatal Committee
NOTE TAKER	Sarah Porter – AOE Consulting
MEMBERS PRESENT:	Debra Heller, Linda Ernst, Philip Katzman, Rebecca Linn, Leon Metlay, Alysa Poulin, Ameet Thaker, Amer Heider, Anna Lee, Ben Wilkins, Carmen Sarita-Reyes, Csaba Calambos, Ivan Gonzalez, Lauren Parsons, William Ryan, Drucilla Roberts, H Pinar, Hernan Correa, Jason Jarzembowski, Jeff Goldstein, Jim Wright, LW, Ona Faye-Persen, Priya Skaria, Rebecca Baergen, Joanne Kubinski (Kellen), Sarah Porter (AOE)
MEMBERS ABSENT:	The Perinatal Business Meeting is open to all SPP members.

I. Call to Order

PRESENTER	Eumenia Castro, MD, PhD (Perinatal Committee Chair)
COMMUNICATION	<ul style="list-style-type: none"> • Dr. Castro called the meeting to order at 11:00 am Eastern Time.

II. Old Business

PRESENTER	Eumenia Castro, MD, PhD (Perinatal Committee Chair)
COMMUNICATION	<ul style="list-style-type: none"> • The first topic addressed at the meeting was the proposal for 2023 submitted by the Children's Hospital of Philadelphia (CHOP). <ul style="list-style-type: none"> ○ It was confirmed that the 2023 Fall Meeting will be hosted by CHOP. ○ It was explained that while the initial theme proposed was fetal stillbirth/unexplained fetal loss, CHOP has come back with a proposal to focus on fetal intervention instead. ○ Dr. Castro summarized the request for the change highlighting that CHOP thinks that fetal intervention is their area of expertise. Dr. Castro also noted that this topic has not been addressed by the SPP in 10 years. ○ There was a comment that highlighted that while the surgery and technical part is interesting, how much pathology will be presented? ○ Dr. Castro clarified that Dr. Rebecca Linn, of CHOP, is a perinatal pathologist. ○ Dr. Linn provided an overview of pathology at CHOP, specifically that there are a number of specimens removed prenatally with a random assortment of individual-type tumors assed. CHOP also sees prenatal resections, twin-twin transfusions, myelomeningocele, fetal occlusion

	<p>for CDH and other pulmonary issues. It was noted that there is a lot of pathology outside of the placenta in addition to tissues taken prenatally.</p> <ul style="list-style-type: none"> ○ It was stated that surgeons and OBGYNs at CHOP are working in the area of stem-cells and artificial placental which might have FDA approval by 2013. As such there is potential for discussion as to strategies and outcomes for different surgeries. ○ Dr. Ben Wilkins, another pathologist at CHOP, discussed the artificial uterus program as well as looking at the effects of intrauterine hypoxia. Dr. Castro clarified that hypoxia examples, however, will not be in the proposal. ○ With regards to the CHOP proposal, it was also noted that Dr. Linn is involved with developing a virtual autopsy program with body radiologists, involving both prenatal and perinatal imaging. ○ It was stated that there are examples of pathology that could be outlined in the proposal that is otherwise quite clinically-based at this juncture. ○ Dr. Castro asked those in attendance if there were any further questions. No further questions were raised. ○ Dr. Ernst reiterated that it would be best to go with expertise of the host site, however, the proposal needs to be further fleshed out. ○ Action: CHOP will update the proposal and bring it back to the Perinatal Committee for approval. ○ Dr. Castro offered to conduct more frequent meetings with the CHOP representatives. ○ Dr. Katzman was the Chair the last time the topic was addressed in 2010; he offered to share the 2010 agenda with CHOP. ○ It was reiterated that the required CME elements (i.e., gap analysis/needs assessment) will need to be completed. It was noted that the prior Perinatal Business Meeting minutes include evidence of prior discussion and documentation. ○ It was further noted that the revised proposal should indicate the following, "This topic was discussed in the Perinatal Business Meeting on March 14, 2021."
VOTE	<ul style="list-style-type: none"> ● There were no formal votes.

III. New Business

PRESENTER #1	Eumenia Castro, MD, PhD, Chair, Perinatal Committee
COMMUNICATION	<ul style="list-style-type: none"> ● Dr. Castro invited those in attendance to discuss proposals for the Fall 2024 meeting, specifically what topics should be addressed. <ul style="list-style-type: none"> ○ It was suggested that the original proposal topic intended for 2023, fetal stillbirth/unexplained fetal loss, could be rolled forward to 2024. ○ Dr. Heller indicated that a site is needed to develop this particular topic. ○ Dr. Castro underscored that the topic and site likely requires some thought and she welcomed individuals to reach out to her directly if they are interested in hosting. ○ There was a question as to whether a venue has been selected for 2024. It was indicated that 2024 has not been selected just yet and that this would be based on the topic and host site. ○ It was further clarified that the Perinatal Symposium is typically at the SPP Fall Meeting and that there will not be a fall site until a proposal is submitted. ○ A summary of upcoming locations was provided as follows: <ul style="list-style-type: none"> ▪ 2021: Portland ▪ 2022: Rochester

	<ul style="list-style-type: none"> ▪ 2023: Philadelphia ▪ 2024: To be determined ○ Dr. Ona Faye-Petersen proposed the topic of immunoregulation, particularly as related to COVID-19, specifically - what cell types are involved, what tissues are involved, what is the damage, what we've been calling X versus what is actually an infection, etc. Ultimately, it was noted that there is a lot of mechanistic elements that will be better understood. ○ Other meeting attendees highlighted additional topics such as chronic placental inflammation in all its various forms, accreta, hysterectomies, and a talk at SMFM on how NK cells control invasiveness which could go in the accreta section. ○ Another attendee noted that at his institution a maternal fetal medicine (MFM) specialist is working with a group involving nanotechnologies and exosomes circulating in the blood and that there may be a blood test to confirm accreta in the near future. ○ It was summarized that there is a lot happening in this field and there was agreement with what Dr. Petersen proposed. ○ It was noted that the last time the topic was addressed was 2004, as noted on the symposium archives outlined on the SPP's website. ○ Dr. Castro indicated that there will be a new Chair of the Perinatal Committee and that all information will be passed along.
VOTE	<ul style="list-style-type: none"> • There was not a formal vote.
PRESENTER #2	Linda Ernst, MD, MHS, Chair, 2021 Perinatal Pathology Course
COMMUNICATION	<ul style="list-style-type: none"> • Dr. Linda Ernst provided an overview of the upcoming Perinatal Pathology Course. <ul style="list-style-type: none"> ○ It was highlighted that the format will be similar to the Spring Meeting to accommodate all time zones. Dr. Ernst ran through the agenda posted online. ○ There was a question as to why CME credit is not being offered for the last session. It was stated that due to the structure of the session being more open, CME is not being offered though attendees can still obtain around 18 or 19 CME credits from the course. ○ One attendees suggested the medical-legal aspect as a potential topic and it was noted that this topic was addressed previously but that it has been a long time. ○ Dr. Pinar raised a question about a pathology group in Nairobi that is very interested in perinatal pathology. While they are interested there are limited funds and they may not be able to attend due to time-zone differences. He indicated that he is willing to contribute funds. ○ It was stated that as long as speakers agree to have the lecture recorded, registered attendees will have access to the recordings for a period of time. ○ It was stated that the Executive Committee is interested in under-resourced countries having access to material and that this is a future focus. ○ There was a discussion as to various approaches and concerns related to recorded content. It was stated that this is a topic being addressed by multiple committees and at the Executive Committee and that it will likely tie into discussions as to future meeting formats.
VOTE	<ul style="list-style-type: none"> • There were no formal votes.

IV. Adjournment

PRESENTER	Eumenia Castro, MD, PhD, Chair, Perinatal Committee
COMMUNICATION	<ul style="list-style-type: none">• The meeting adjourned at 11:44 am Eastern Time.